Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Acute coronary syndromes (ACS) are still associated with high morbidity and mortality,
despite several improvements in their management. This may indicate that important pathogenic
mechanisms contribute to both stable and unstable atherosclerotic disease mechanisms.
Based upon previous research, the investigators believe that providing a block in the
damaging inflammatory loop though short term inhibition of Interleukin-6 receptor signalling,
could be an attractive therapeutic target in ACS; and of particular interest in patients with
non-ST elevation myocardial infarction (NSTEMI), a disease often characterized by widespread
coronary inflammation with multiple unstable plaques.
The investigators hypothesize that a single administration of the anti-Interleukin 6 receptor
antagonist Tocilizumab, in patients with NSTEMI, may interrupt the self-perpetuating
inflammatory loops which could improve plaque stability, with potential secondary beneficial
effects on myocardial damage.
This will be investigated in a randomized, double blind, placebo-controlled study, including
a total of 120 patients.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Norwegian University of Science and Technology South-Eastern Norway Regional Health Authority St. Olavs Hospital University of Oslo